SCHEMBL3313129

SCHEMBL3313129

COc1cc(C(=O)NCC#N)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.36
CD274 Q9NZQ7 1/20 0.35
GAA P10253 3/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
BLM P54132 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
EPHX2 P34913 1/20 0.34
NR1H4 Q96RI1 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
IMPDH2 P12268 1/20 0.33
IMPDH1 P20839 1/20 0.33
CYP1A1 P04798 1/20 0.33
EZH2 Q15910 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362083 0.85 PLK1 (0.38) CYP3A4CD274GAAPOLBKDM4E
SCHEMBL3311118 0.84 CYP3A4 (0.35) CYP3A4CD274GAAKDM4EL3MBTL1
SCHEMBL2350724 0.82 NAPRT (0.43) CYP3A4KDM4EL3MBTL1EPHX2NR1H4
SCHEMBL2349673 0.81 CYP1A1 (0.37) CYP3A4CD274L3MBTL1IMPDH2IMPDH1
SCHEMBL2355139 0.80 RAB9A (0.39) GAAKDM4EMEN1KMT2AL3MBTL1
SCHEMBL2354432 0.79 KDM4E (0.40) CYP3A4GAAPOLBKDM4EMAPT
SCHEMBL3316087 0.79 MAP4K1 (0.38) CYP3A4CD274MEN1KMT2AMAPT
SCHEMBL3310183 0.77 KCNH2 (0.37) CYP3A4CD274KDM4ECYP1A1
SCHEMBL3308176 0.76 CYP3A4 (0.42) CYP3A4GAAPOLBKDM4EMEN1
SCHEMBL2350049 0.76 LPAR5 (0.42) MEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885CD274 3932/4885GAA 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.